Cytek Biosciences, Inc. (CTKB) Financial Statements
Cytek Biosciences, Inc. (CTKB) reported trailing twelve-month revenue of $206.7M (up 5.4% year on year) and net income of -$80.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$12.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTKBCytek Biosciences, Inc.Follow CTKB — free
—
Price chart with a free account
- Market cap
- 726.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 128.0 | 164.0 | 193.0 | 200.5 | 201.5 | 206.7 | |
| Gross profit | 79.1 | 101.0 | 109.4 | 111.1 | 104.5 | 110.0 | |
| Research & development | 24.4 | 34.9 | 44.2 | 39.4 | 36.5 | 37.3 | |
| Operating income | 9.2 | -1.8 | -27.8 | -20.5 | -40.4 | -44.6 | |
| Pre-tax income | 5.9 | 1.3 | -15.7 | -5.7 | -29.8 | -40.8 | |
| Income tax | 2.9 | -1.2 | -3.6 | 0.3 | 36.7 | 39.8 | |
| Net income | 3.0 | 2.5 | -12.1 | -6.0 | -66.5 | -80.6 | |
| Diluted EPS ($) | 0.00 | 0.02 | -0.09 | -0.05 | -0.52 | -0.63 | |
| Diluted shares (mn) | 81.5 | 138.6 | 135.3 | 130.6 | 127.7 | — |
USD millions · SEC XBRL
Cytek Biosciences, Inc. — questions
- What is Cytek Biosciences, Inc.'s revenue?
- $206.7M over the twelve months to 2026-06-30, up 5.4% year on year, from its 10-Q and 10-K filings.
- What is Cytek Biosciences, Inc.'s net income?
- -$80.6M over the twelve months to 2026-06-30.
- What is Cytek Biosciences, Inc.'s free cash flow?
- -$12.1M over the twelve months to 2026-06-30.
- What are Cytek Biosciences, Inc.'s diluted earnings per share?
- $-0.63 over the twelve months to 2026-06-30.
Every figure on this page comes from Cytek Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.